Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
36 authors.
Paul J HooverDivision of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5343-429X
Chirag RapariaInstitute of Molecular Medicine, Feinstein Institutes for Medical Research , Manhasset, NY, USA.ORCID 0000-0002-5361-1257
Jeffrey B HodginDepartment of Pathology, University of Michigan, Ann Arbor, Ann Arbor, Michigan, USA.ORCID 0000-0003-0534-3048
Celine C BerthierDepartment of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-3539-1075
Joel M GuthridgeDepartment of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.ORCID 0000-0002-9308-237X
Andrea FavaDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0001-6738-4836
Robert M ClancyDivision of Rheumatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-1151-0084
Chaim PuttermanDivision of Rheumatology and Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-3204-6068
Peter M IzmirlyDivision of Rheumatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0000-0001-5445-2182
H Michael BelmontDivision of Rheumatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-3389-2976
Kenneth KalunianDivision of Rheumatology, Autoimmunity and Inflammation, University of California, San Diego School of Medicine, San Diego, CA, USA.ORCID 0000-0003-0261-3102
Diane KamenDepartment of Medicine, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0002-7698-980X
David WofsyRheumatology Division, Department of Medicine, Russell/Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8350-3428
Jill P BuyonDepartment of Pathology, University of Michigan, Ann Arbor, Ann Arbor, Michigan, USA.ORCID 0000-0002-3852-7129
Judith A JamesProgram in Medical and Population Genetics, Broad Institute of MIT and Harvard , Cambridge, MA, USA.ORCID 0000-0002-9574-7355
Michelle PetriDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1441-5373
Betty DiamondInstitute of Molecular Medicine, Feinstein Institutes for Medical Research , Manhasset, NY, USA.ORCID 0000-0002-3250-3804
Soumya RaychaudhuriDivision of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1901-8265
Shai S Shen-OrrRappaport Faculty of Medicine, Technion - Israel Institute of Technology , Haifa, Israel.ORCID 0000-0002-6991-7736
Accelerating Medicines Partnership in RA/SLE network
Anne Davidson *Institute of Molecular Medicine, Feinstein Institutes for Medical Research , Manhasset, NY, USA.ORCID 0000-0002-4081-6464
Funding
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core Admin Supplement: Preclinical Studies in Sjogren'sUC2AR081032 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI Joel Marvin Guthridge, JUDITH A JAMES · 2022 to 2026
$30.7M
Central Hub for Kidney Precision MedicineU24DK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$21.1M
KPMP Kidney Mapping and Atlas Project (KMAP)U01DK133090 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$10.4M
Integrated spatial interrogation of cellular and molecular signatures of human kidney diseaseU01DK114923 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Tarek Maurice Ashkar, Pierre C Dagher · 2022 to 2026
$5.4M
Single cell multiomic and spatial atlas of acute and chronic kidney injuryU01DK114933 · NIDDK · WASHINGTON UNIVERSITY · PI Sanjay Jain · 2022 to 2026
$5.0M
Spatial Multi-Omics to Profile Metabolic Pathways for Kidney DiseaseU01DK114920 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Christopher R Anderton, Kumar Sharma · 2022 to 2026
$3.9M
Boston Chronic Kidney Disease Research Biopsy CenterU01DK133092 · NIDDK · BOSTON MEDICAL CENTER · PI Sylvia E Rosas, Sushrut S. Waikar · 2022 to 2026
$3.5M
Multimodal Imaging Mass Spectrometry and Spatial Omics for the Human KidneyU01DK133766 · NIDDK · VANDERBILT UNIVERSITY · PI Jeffrey M Spraggins · 2022 to 2026
$3.4M
PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE)U01DK114907 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Nir Hacohen, Jeffrey Benton Hodgin · 2022 to 2026
$3.2M
University of Illinois at Chicago KPMP CKD Recruitment SiteU01DK133081 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI JAMES P. LASH, Ana Catherine Ricardo · 2022 to 2026
$2.7M
AKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue)U01DK114866 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Chirag R Parikh · 2022 to 2026
$2.6M
Dissecting the heterogeneity and function of myeloid cells in lupus nephritisR01DK131482 · NIDDK · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI Anne Davidson · 2023 to 2026
Monocytes and macrophages in patients with lupus nephritis exhibit altered behavior compared with healthy kidneys. How to optimally use mouse models to develop treatments targeting these cells is poorly understood. This study compared intrarenal myeloid cells in four mouse models and 155 lupus nephritis patients using single-cell profiling, spatial transcriptomics, and functional studies. Across mouse models, monocyte and macrophage subsets consistently expanded or contracted in disease. A subset of murine classical monocytes expanded in disease; these cells expressed Cd9, Spp1, Ctsd, Cd63, Apoe, and Trem2, genes associated with tissue injury in other organs that play roles in inflammation, lipid metabolism, and tissue repair. Resident macrophages expressed similar genes in clinical disease. In humans, we identified analogous disease-associated monocytes and macrophages that were associated with kidney histological subtypes and disease progression, sharing gene expression and localizing to similar kidney microenvironments as in mice. This cross-species analysis supports the use of mouse functional studies for understanding human lupus nephritis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A human-mouse atlas of intrarenal myeloid cells identifies conserved disease-associated macrophages in lupus nephritis. · full record | OpenQuestion